

### **COMPANY OVERVIEW**

BioCorRx® is a leading-edge healthcare solutions company focused on improving the lives of those struggling with alcohol, opioid, and other addictive disorders. Designed to address alcoholism and certain opioid addictions, the Beat Addiction Recovery Program is used by independent treatment centers or physicians in the United States. The program consists of BioCorRx's proprietary cognitive behavioral therapy (CBT) program and peer recovery support mobile application and may include the use of certain medications typically used for the treatment of substance use disorder (SUD). Which medication used, if any, is at the sole discretion of the treating physician in consultation with their patient. The most common medication used in the program is naltrexone in various forms (oral, injectable, implantable pellet). The company does not sell, manufacture, or compound any drugs or pharmaceuticals. The company also has a pharmaceutical subsidiary, BioCorRx Pharmaceuticals, which is developing medications for future regulatory approval. It's lead candidate is a biodegradable implantable naltrexone pellet for alcohol and opioid use disorders.

### **MANAGEMENT TEAM**

**Lourdes Felix** 

CEO, CFO, and Director

**Louis Lucido** 

President & Director

Dr. Joseph DeSanto

Medical Director Consultant

**Dr. John Dombrowski**Medical Director Consultant

Dr. George Fallieras

Medical Director Consultant

### **RECENT NEWS**

BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th

Dec 10 2025, 8:35 AM EST

BioCorRx, Inc. Announces Q3 2025 Results: Second Straight Quarter of Meaningful Revenue Driven by LUCEMYRA(R) Acquisition

Nov 18 2025, 8:39 AM EST

BioCorRx Reports 3,985% Revenue Growth to \$313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales

Aug 14 2025, 2:32 PM EDT

# **BIOCORRX, INC.**

2390 E. Orangewood Ave. Suite 570 Anaheim. CA 92806

# **STOCK OVERVIEW**

Symbol BICX

Exchange OTCQB

Market Cap 9.19m

Last Price \$0.3881

**52-Week Range** \$0.1995 - \$1.45

12/10/2025 02:32 PM EST

# **INVESTOR RELATIONS**

Crescendo Communications, LLC T: 212-671-1020 x304

bicx@crescendo-ir.com

investors@biocorrx.com

# **DISCLAIMER**

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.